CN101677973A - 用于抑制神经传导的包括萜烯化合物的组合物以及方法 - Google Patents
用于抑制神经传导的包括萜烯化合物的组合物以及方法 Download PDFInfo
- Publication number
- CN101677973A CN101677973A CN200880006917A CN200880006917A CN101677973A CN 101677973 A CN101677973 A CN 101677973A CN 200880006917 A CN200880006917 A CN 200880006917A CN 200880006917 A CN200880006917 A CN 200880006917A CN 101677973 A CN101677973 A CN 101677973A
- Authority
- CN
- China
- Prior art keywords
- pain
- dimethyl
- unbranched
- compositions
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 136
- -1 terpene compounds Chemical class 0.000 title claims abstract description 69
- 238000000034 method Methods 0.000 title claims abstract description 48
- 235000007586 terpenes Nutrition 0.000 title claims abstract description 48
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 21
- 230000005540 biological transmission Effects 0.000 title abstract description 7
- 210000005036 nerve Anatomy 0.000 title description 6
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 claims abstract description 90
- 150000001875 compounds Chemical class 0.000 claims abstract description 77
- 238000011282 treatment Methods 0.000 claims abstract description 59
- QMVPMAAFGQKVCJ-UHFFFAOYSA-N citronellol Chemical compound OCCC(C)CCC=C(C)C QMVPMAAFGQKVCJ-UHFFFAOYSA-N 0.000 claims abstract description 50
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 claims abstract description 42
- 239000005792 Geraniol Substances 0.000 claims abstract description 42
- 229940113087 geraniol Drugs 0.000 claims abstract description 42
- 235000000484 citronellol Nutrition 0.000 claims abstract description 26
- QMVPMAAFGQKVCJ-SNVBAGLBSA-N (R)-(+)-citronellol Natural products OCC[C@H](C)CCC=C(C)C QMVPMAAFGQKVCJ-SNVBAGLBSA-N 0.000 claims abstract description 25
- JGQFVRIQXUFPAH-UHFFFAOYSA-N beta-citronellol Natural products OCCC(C)CCCC(C)=C JGQFVRIQXUFPAH-UHFFFAOYSA-N 0.000 claims abstract description 25
- 208000002193 Pain Diseases 0.000 claims description 147
- 230000036407 pain Effects 0.000 claims description 145
- 230000002981 neuropathic effect Effects 0.000 claims description 77
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 28
- 125000004423 acyloxy group Chemical group 0.000 claims description 28
- 125000003545 alkoxy group Chemical group 0.000 claims description 28
- 125000000217 alkyl group Chemical group 0.000 claims description 28
- 239000003814 drug Substances 0.000 claims description 28
- 150000003505 terpenes Chemical class 0.000 claims description 25
- WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 claims description 21
- 150000002148 esters Chemical class 0.000 claims description 19
- NEHNMFOYXAPHSD-UHFFFAOYSA-N citronellal Chemical compound O=CCC(C)CCC=C(C)C NEHNMFOYXAPHSD-UHFFFAOYSA-N 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 18
- 238000002360 preparation method Methods 0.000 claims description 17
- 230000007830 nerve conduction Effects 0.000 claims description 16
- 239000012453 solvate Substances 0.000 claims description 15
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims description 14
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical class OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 12
- 239000000839 emulsion Substances 0.000 claims description 12
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 12
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 claims description 11
- 239000003085 diluting agent Substances 0.000 claims description 11
- 208000011580 syndromic disease Diseases 0.000 claims description 11
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
- CZCBTSFUTPZVKJ-UHFFFAOYSA-N rose oxide Chemical compound CC1CCOC(C=C(C)C)C1 CZCBTSFUTPZVKJ-UHFFFAOYSA-N 0.000 claims description 10
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 9
- DZNVIZQPWLDQHI-UHFFFAOYSA-N Citronellyl formate Chemical compound O=COCCC(C)CCC=C(C)C DZNVIZQPWLDQHI-UHFFFAOYSA-N 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- IAQRGUVFOMOMEM-UHFFFAOYSA-N butene Natural products CC=CC IAQRGUVFOMOMEM-UHFFFAOYSA-N 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 8
- 241000134874 Geraniales Species 0.000 claims description 7
- 229930003633 citronellal Natural products 0.000 claims description 7
- 235000000983 citronellal Nutrition 0.000 claims description 7
- 208000015181 infectious disease Diseases 0.000 claims description 7
- 230000000699 topical effect Effects 0.000 claims description 7
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims description 6
- OGHBUHJLMHQMHS-UHFFFAOYSA-N 3,7-dimethylocta-2,6-dienyl 2-methylbut-2-enoate Chemical compound CC=C(C)C(=O)OCC=C(C)CCC=C(C)C OGHBUHJLMHQMHS-UHFFFAOYSA-N 0.000 claims description 6
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 6
- 206010044652 trigeminal neuralgia Diseases 0.000 claims description 6
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 claims description 5
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 claims description 5
- 208000001387 Causalgia Diseases 0.000 claims description 5
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 claims description 5
- 208000007514 Herpes zoster Diseases 0.000 claims description 5
- ZSBOMYJPSRFZAL-JLHYYAGUSA-N [(2e)-3,7-dimethylocta-2,6-dienyl] butanoate Chemical compound CCCC(=O)OC\C=C(/C)CCC=C(C)C ZSBOMYJPSRFZAL-JLHYYAGUSA-N 0.000 claims description 5
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 229930007744 linalool Natural products 0.000 claims description 5
- 201000006417 multiple sclerosis Diseases 0.000 claims description 5
- SHPVOXFREBUEHB-UHFFFAOYSA-N oct-6-en-1-ol Chemical compound CC=CCCCCCO SHPVOXFREBUEHB-UHFFFAOYSA-N 0.000 claims description 5
- 239000006187 pill Substances 0.000 claims description 5
- 229930007790 rose oxide Natural products 0.000 claims description 5
- NFLGAXVYCFJBMK-RKDXNWHRSA-N (+)-isomenthone Natural products CC(C)[C@H]1CC[C@@H](C)CC1=O NFLGAXVYCFJBMK-RKDXNWHRSA-N 0.000 claims description 4
- VVUMWAHNKOLVSN-UHFFFAOYSA-N 2-(4-ethoxyanilino)-n-propylpropanamide Chemical compound CCCNC(=O)C(C)NC1=CC=C(OCC)C=C1 VVUMWAHNKOLVSN-UHFFFAOYSA-N 0.000 claims description 4
- IYYUJCKJSSPXQQ-UHFFFAOYSA-N 2-pyridin-4-yl-1,3-thiazolidin-3-ium-4-carboxylate Chemical compound N1C(C(=O)O)CSC1C1=CC=NC=C1 IYYUJCKJSSPXQQ-UHFFFAOYSA-N 0.000 claims description 4
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 208000017667 Chronic Disease Diseases 0.000 claims description 4
- XQPZQXTWYZAXAK-UHFFFAOYSA-N Citronellyl butyrate Chemical compound CCCC(=O)OCCC(C)CCC=C(C)C XQPZQXTWYZAXAK-UHFFFAOYSA-N 0.000 claims description 4
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 claims description 4
- 208000001640 Fibromyalgia Diseases 0.000 claims description 4
- NFLGAXVYCFJBMK-UHFFFAOYSA-N Menthone Chemical compound CC(C)C1CCC(C)CC1=O NFLGAXVYCFJBMK-UHFFFAOYSA-N 0.000 claims description 4
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 claims description 4
- 229910019142 PO4 Inorganic materials 0.000 claims description 4
- 208000004983 Phantom Limb Diseases 0.000 claims description 4
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 claims description 4
- 208000008765 Sciatica Diseases 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 208000016097 disease of metabolism Diseases 0.000 claims description 4
- 235000019253 formic acid Nutrition 0.000 claims description 4
- FQMZVFJYMPNUCT-UHFFFAOYSA-N geraniol formate Natural products CC(C)=CCCC(C)=CCOC=O FQMZVFJYMPNUCT-UHFFFAOYSA-N 0.000 claims description 4
- NHCQMVNKPJAQJZ-UHFFFAOYSA-N geranyl n-butyrate Natural products CCCCOCC=C(C)CCC=C(C)C NHCQMVNKPJAQJZ-UHFFFAOYSA-N 0.000 claims description 4
- 229930007503 menthone Natural products 0.000 claims description 4
- 208000030159 metabolic disease Diseases 0.000 claims description 4
- 230000004768 organ dysfunction Effects 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 4
- 239000010452 phosphate Substances 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 239000003440 toxic substance Substances 0.000 claims description 4
- 208000019553 vascular disease Diseases 0.000 claims description 4
- QPBVYDIIQIYFQO-UHFFFAOYSA-N 3,7-dimethyloct-6-enyl prop-2-enoate Chemical compound CC(C)=CCCC(C)CCOC(=O)C=C QPBVYDIIQIYFQO-UHFFFAOYSA-N 0.000 claims description 3
- GLZPCOQZEFWAFX-JXMROGBWSA-N Nerol Natural products CC(C)=CCC\C(C)=C\CO GLZPCOQZEFWAFX-JXMROGBWSA-N 0.000 claims description 3
- 239000000443 aerosol Substances 0.000 claims description 3
- 150000001408 amides Chemical class 0.000 claims description 3
- 150000001412 amines Chemical class 0.000 claims description 3
- 231100000481 chemical toxicant Toxicity 0.000 claims description 3
- WTEVQBCEXWBHNA-YFHOEESVSA-N citral B Natural products CC(C)=CCC\C(C)=C/C=O WTEVQBCEXWBHNA-YFHOEESVSA-N 0.000 claims description 3
- 230000030214 innervation Effects 0.000 claims description 3
- 208000004454 Hyperalgesia Diseases 0.000 claims description 2
- 206010053552 allodynia Diseases 0.000 claims description 2
- WUOACPNHFRMFPN-VIFPVBQESA-N (R)-(+)-alpha-terpineol Chemical compound CC1=CC[C@H](C(C)(C)O)CC1 WUOACPNHFRMFPN-VIFPVBQESA-N 0.000 claims 2
- 231100000862 numbness Toxicity 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 13
- 239000002552 dosage form Substances 0.000 abstract description 6
- 208000004296 neuralgia Diseases 0.000 abstract description 6
- 239000000341 volatile oil Substances 0.000 abstract description 6
- 210000002569 neuron Anatomy 0.000 abstract description 5
- 208000021722 neuropathic pain Diseases 0.000 abstract description 3
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 43
- 239000003921 oil Substances 0.000 description 31
- 235000019198 oils Nutrition 0.000 description 31
- 238000012360 testing method Methods 0.000 description 22
- 241000196324 Embryophyta Species 0.000 description 14
- 241000628997 Flos Species 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 238000011160 research Methods 0.000 description 11
- 238000000746 purification Methods 0.000 description 10
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 9
- 239000013543 active substance Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 230000004044 response Effects 0.000 description 8
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 7
- 238000004821 distillation Methods 0.000 description 7
- 229960003299 ketamine Drugs 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 102000004257 Potassium Channel Human genes 0.000 description 6
- 239000001961 anticonvulsive agent Substances 0.000 description 6
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 210000003618 cortical neuron Anatomy 0.000 description 6
- 230000003111 delayed effect Effects 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 108020001213 potassium channel Proteins 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 5
- 230000000202 analgesic effect Effects 0.000 description 5
- 230000001773 anti-convulsant effect Effects 0.000 description 5
- 229960003965 antiepileptics Drugs 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000020341 sensory perception of pain Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 108091006146 Channels Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241000208152 Geranium Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 241000208181 Pelargonium Species 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- ULDHMXUKGWMISQ-UHFFFAOYSA-N carvone Chemical compound CC(=C)C1CC=C(C)C(=O)C1 ULDHMXUKGWMISQ-UHFFFAOYSA-N 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 229960002870 gabapentin Drugs 0.000 description 4
- 210000001320 hippocampus Anatomy 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 208000035824 paresthesia Diseases 0.000 description 4
- 230000002085 persistent effect Effects 0.000 description 4
- 229930004725 sesquiterpene Natural products 0.000 description 4
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 206010008190 Cerebrovascular accident Diseases 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 241001597008 Nomeidae Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 229940035676 analgesics Drugs 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000000730 antalgic agent Substances 0.000 description 3
- 239000000935 antidepressant agent Substances 0.000 description 3
- 229940005513 antidepressants Drugs 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 229960002504 capsaicin Drugs 0.000 description 3
- 235000017663 capsaicin Nutrition 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 206010015037 epilepsy Diseases 0.000 description 3
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 3
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 229960001848 lamotrigine Drugs 0.000 description 3
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 3
- 239000007937 lozenge Substances 0.000 description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 235000013599 spices Nutrition 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 229940125725 tranquilizer Drugs 0.000 description 3
- 239000003204 tranquilizing agent Substances 0.000 description 3
- 230000002936 tranquilizing effect Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 2
- 241000218236 Cannabis Species 0.000 description 2
- 239000005973 Carvone Substances 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- 206010012335 Dependence Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 244000178870 Lavandula angustifolia Species 0.000 description 2
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 206010033425 Pain in extremity Diseases 0.000 description 2
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 206010041349 Somnolence Diseases 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000036982 action potential Effects 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- WUOACPNHFRMFPN-UHFFFAOYSA-N alpha-terpineol Chemical compound CC1=CCC(C(C)(C)O)CC1 WUOACPNHFRMFPN-UHFFFAOYSA-N 0.000 description 2
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 2
- 229960000836 amitriptyline Drugs 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 230000003288 anthiarrhythmic effect Effects 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000003502 anti-nociceptive effect Effects 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 229940125713 antianxiety drug Drugs 0.000 description 2
- 239000003416 antiarrhythmic agent Substances 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 229960000794 baclofen Drugs 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 2
- 229960000623 carbamazepine Drugs 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000000080 chela (arthropods) Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- RWGFKTVRMDUZSP-UHFFFAOYSA-N cumene Chemical compound CC(C)C1=CC=CC=C1 RWGFKTVRMDUZSP-UHFFFAOYSA-N 0.000 description 2
- SQIFACVGCPWBQZ-UHFFFAOYSA-N delta-terpineol Natural products CC(C)(O)C1CCC(=C)CC1 SQIFACVGCPWBQZ-UHFFFAOYSA-N 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 229930004069 diterpene Natural products 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000005496 eutectics Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008241 heterogeneous mixture Substances 0.000 description 2
- 230000000971 hippocampal effect Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 230000000622 irritating effect Effects 0.000 description 2
- 229960004194 lidocaine Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000028161 membrane depolarization Effects 0.000 description 2
- 229940041616 menthol Drugs 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 229930003658 monoterpene Natural products 0.000 description 2
- 150000002773 monoterpene derivatives Chemical class 0.000 description 2
- 235000002577 monoterpenes Nutrition 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000003158 myorelaxant agent Substances 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 238000006213 oxygenation reaction Methods 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 239000001298 pelargonium graveolens oil Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229960002036 phenytoin Drugs 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 208000028173 post-traumatic stress disease Diseases 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 238000012797 qualification Methods 0.000 description 2
- KKOXKGNSUHTUBV-UHFFFAOYSA-N racemic zingiberene Natural products CC(C)=CCCC(C)C1CC=C(C)C=C1 KKOXKGNSUHTUBV-UHFFFAOYSA-N 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000000273 spinal nerve root Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229940116411 terpineol Drugs 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- KKOXKGNSUHTUBV-LSDHHAIUSA-N zingiberene Chemical compound CC(C)=CCC[C@H](C)[C@H]1CC=C(C)C=C1 KKOXKGNSUHTUBV-LSDHHAIUSA-N 0.000 description 2
- 229930001895 zingiberene Natural products 0.000 description 2
- LFJQCDVYDGGFCH-UHFFFAOYSA-N β-phellandrene Chemical compound CC(C)C1CCC(=C)C=C1 LFJQCDVYDGGFCH-UHFFFAOYSA-N 0.000 description 2
- PHWISBHSBNDZDX-UHFFFAOYSA-N β-sesquiphellandrene Chemical compound CC(C)=CCCC(C)C1CCC(=C)C=C1 PHWISBHSBNDZDX-UHFFFAOYSA-N 0.000 description 2
- DTGKSKDOIYIVQL-NQMVMOMDSA-N (+)-Borneol Natural products C1C[C@]2(C)[C@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-NQMVMOMDSA-N 0.000 description 1
- DTGKSKDOIYIVQL-QXFUBDJGSA-N (-)-borneol Chemical compound C1C[C@]2(C)[C@H](O)C[C@H]1C2(C)C DTGKSKDOIYIVQL-QXFUBDJGSA-N 0.000 description 1
- 229930006703 (-)-borneol Natural products 0.000 description 1
- GDDAJHJRAKOILH-QFXXITGJSA-N (2e,5e)-octa-2,5-diene Chemical compound CC\C=C\C\C=C\C GDDAJHJRAKOILH-QFXXITGJSA-N 0.000 description 1
- WUOACPNHFRMFPN-SECBINFHSA-N (S)-(-)-alpha-terpineol Chemical compound CC1=CC[C@@H](C(C)(C)O)CC1 WUOACPNHFRMFPN-SECBINFHSA-N 0.000 description 1
- 239000001169 1-methyl-4-propan-2-ylcyclohexa-1,4-diene Substances 0.000 description 1
- UCFQYMKLDPWFHZ-MKMNVTDBSA-N 3,7-dimethyloct-6-enyl (e)-2-methylbut-2-enoate Chemical compound C\C=C(/C)C(=O)OCCC(C)CCC=C(C)C UCFQYMKLDPWFHZ-MKMNVTDBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010013886 Dysaesthesia Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 240000004859 Gamochaeta purpurea Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010026389 Gramicidin Proteins 0.000 description 1
- LQSMEVHEYXACJP-DSHASFMGSA-N Gramicidin B Chemical compound C([C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCCO)C1=CC=CC=C1 LQSMEVHEYXACJP-DSHASFMGSA-N 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- 206010065952 Hyperpathia Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010701 Lavanda vera Nutrition 0.000 description 1
- 244000042664 Matricaria chamomilla Species 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 208000001294 Nociceptive Pain Diseases 0.000 description 1
- 102000003840 Opioid Receptors Human genes 0.000 description 1
- 108090000137 Opioid Receptors Proteins 0.000 description 1
- 244000270673 Pelargonium graveolens Species 0.000 description 1
- 235000017927 Pelargonium graveolens Nutrition 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000005793 Restless legs syndrome Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 244000082988 Secale cereale Species 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 244000126014 Valeriana officinalis Species 0.000 description 1
- 235000013832 Valeriana officinalis Nutrition 0.000 description 1
- 241000234314 Zingiber Species 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- OVKDFILSBMEKLT-UHFFFAOYSA-N alpha-Terpineol Natural products CC(=C)C1(O)CCC(C)=CC1 OVKDFILSBMEKLT-UHFFFAOYSA-N 0.000 description 1
- 229940088601 alpha-terpineol Drugs 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 239000010692 aromatic oil Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000005388 borosilicate glass Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000007765 cera alba Substances 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- RFFOTVCVTJUTAD-UHFFFAOYSA-N cineole Natural products C1CC2(C)CCC1(C(C)C)O2 RFFOTVCVTJUTAD-UHFFFAOYSA-N 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- 229940043350 citral Drugs 0.000 description 1
- 150000001862 citronellol derivatives Chemical class 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002079 cooperative effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 229960001985 dextromethorphan Drugs 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 150000004141 diterpene derivatives Chemical class 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000004508 fractional distillation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- WWULHQLTPGKDAM-UHFFFAOYSA-N gamma-eudesmol Natural products CC(C)C1CC(O)C2(C)CCCC(=C2C1)C WWULHQLTPGKDAM-UHFFFAOYSA-N 0.000 description 1
- 230000000574 ganglionic effect Effects 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 231100000734 genotoxic potential Toxicity 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 210000004295 hippocampal neuron Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 1
- 208000016290 incoordination Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000000077 insect repellent Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000018219 lavender Nutrition 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 150000002729 menthone derivatives Chemical class 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000008062 neuronal firing Effects 0.000 description 1
- 229940072228 neurontin Drugs 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 1
- 206010029864 nystagmus Diseases 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 150000007875 phellandrene derivatives Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000007824 polyneuropathy Effects 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical class [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229940124606 potential therapeutic agent Drugs 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229930002224 sesquiphellandrene Natural products 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 210000002356 skeleton Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000007885 tablet disintegrant Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 150000003535 tetraterpenes Chemical class 0.000 description 1
- 235000009657 tetraterpenes Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 235000016788 valerian Nutrition 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/121—Ketones acyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Mycology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Dispersion Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
Abstract
Description
Claims (36)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201511021134.2A CN105581999A (zh) | 2007-02-06 | 2008-02-06 | 用于抑制神经传导的包括萜烯化合物的组合物以及方法 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US89964207P | 2007-02-06 | 2007-02-06 | |
US60/899,642 | 2007-02-06 | ||
PCT/CA2008/000236 WO2008095297A1 (en) | 2007-02-06 | 2008-02-06 | Composition comprising terpene compounds and methods for inhibiting nerve transmission |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201511021134.2A Division CN105581999A (zh) | 2007-02-06 | 2008-02-06 | 用于抑制神经传导的包括萜烯化合物的组合物以及方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101677973A true CN101677973A (zh) | 2010-03-24 |
Family
ID=39681217
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201511021134.2A Pending CN105581999A (zh) | 2007-02-06 | 2008-02-06 | 用于抑制神经传导的包括萜烯化合物的组合物以及方法 |
CN200880006917A Pending CN101677973A (zh) | 2007-02-06 | 2008-02-06 | 用于抑制神经传导的包括萜烯化合物的组合物以及方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201511021134.2A Pending CN105581999A (zh) | 2007-02-06 | 2008-02-06 | 用于抑制神经传导的包括萜烯化合物的组合物以及方法 |
Country Status (9)
Country | Link |
---|---|
US (2) | US9999601B2 (zh) |
EP (1) | EP2142182B1 (zh) |
JP (2) | JP5933164B2 (zh) |
KR (2) | KR20150046328A (zh) |
CN (2) | CN105581999A (zh) |
AU (1) | AU2008213772A1 (zh) |
CA (1) | CA2676139C (zh) |
HK (1) | HK1224231A1 (zh) |
WO (1) | WO2008095297A1 (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103153297A (zh) * | 2010-09-14 | 2013-06-12 | 安元有限公司 | 类萜类似物及其用于治疗神经病症的用途 |
CN104284668A (zh) * | 2012-05-07 | 2015-01-14 | 以色列国家农业和农村发展部农业科研组织(Aro)(沃尔卡尼中心) | 用于治疗神经变性疾病的天竺葵精油及其成分 |
CN104918614A (zh) * | 2012-09-28 | 2015-09-16 | 株式会社资生堂 | Vegfc产生促进剂 |
CN105637363A (zh) * | 2013-08-01 | 2016-06-01 | 庆熙大学校产学协力团 | 预防或治疗糖尿病的药物组合物,预防或治疗糖尿病的方法,以及筛选糖尿病治疗药物的方法 |
US11311497B2 (en) | 2013-08-01 | 2022-04-26 | University—Industry Corporation Group of Kyung Hee University | Method for screening for diabetes mellitus therapeutic agents |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5933164B2 (ja) | 2007-02-06 | 2016-06-08 | ニューロクエスト インク | テルペン化合物を含む組成物及び神経伝達の抑制方法 |
EP2131827A2 (en) | 2007-03-09 | 2009-12-16 | New York University | Methods and compositions for treating thalamocortical dysrhythmia |
EP2326323A4 (en) * | 2008-08-13 | 2012-02-22 | Neuroquest Inc | COMPOSITION COMPRISING TERPENE COMPOUNDS FOR THE TREATMENT OF NEGATIVE SENSORY PHENOMENA |
US20130203711A1 (en) * | 2010-10-18 | 2013-08-08 | Anil Kumar Gupta | Novel herbal oil for controlling blood sugar without risk of hypoglycemea |
CA2841972A1 (en) * | 2011-07-14 | 2013-01-17 | Neuroquest Inc. | Terpene analogues and uses thereof for treating neurological conditions |
US9228727B2 (en) | 2012-04-05 | 2016-01-05 | Michael W. May | Lighting assembly |
CA2908348C (en) * | 2013-05-24 | 2021-05-25 | Nestec S.A. | Treatment or prevention of autism disorders using menthol, linalool and/or icilin |
KR102250582B1 (ko) | 2018-05-11 | 2021-05-12 | 고려대학교 산학협력단 | 별아교세포 특이적 수동전도도 억제약물의 스크리닝 시스템 및 이의 활용 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1555333A (en) | 1975-05-29 | 1979-11-07 | Bush Boake Allen Ltd | Perfumery compositions comprising hydroxy- or alkoxy-substituted c9 alkanals alkanols and esters |
NZ190416A (en) | 1978-05-16 | 1981-05-29 | Unilever Ltd | Deodorant product |
ES2004736A6 (es) | 1986-05-08 | 1989-02-01 | R & C Products Pty Ltd | Composicion repelente de animales composicion de cebo molusquicida metodo de prepararlas y procedimiento de controlar plagas |
EP0252290B1 (en) | 1986-06-10 | 1992-06-03 | CHIESI FARMACEUTICI S.p.A. | Pharmaceutical compositions containing levodopa methyl ester, preparation and therapeutic applications thereof |
DE3725248A1 (de) | 1987-07-30 | 1989-02-09 | Henkel Kgaa | Antimikrobiell wirksame, aromatisierte zubereitungen |
US5770738A (en) | 1992-03-05 | 1998-06-23 | Boehringer Ingelheim Kg | Esters of bi- and tricyclic amino alcohols, their preparation and their use in pharmaceutical compositions |
US5260313A (en) * | 1992-03-12 | 1993-11-09 | National Pain Institute, Inc. | Diagnosis and treatment of various neuralgias |
US6248307B1 (en) | 1999-04-14 | 2001-06-19 | Standard Homeopathic Company | Compositions and treatment for alleviation of symptoms associated with menopause |
KR100968356B1 (ko) * | 2001-08-08 | 2010-07-06 | 가부시키가이샤 시세이도 | 향료 조성물 |
CA2465952A1 (en) | 2001-11-06 | 2003-05-15 | Ortho-Mcneil Pharmaceutical, Inc. | Treatment and prevention of paresthesia comprising co-therapy with anticonvulsant derivatives and potassium |
US20030180349A1 (en) * | 2001-12-07 | 2003-09-25 | Franklin Lanny U. | Respiratory infection prevention and treatment with terpene-containing compositions |
US20030224072A1 (en) * | 2002-06-03 | 2003-12-04 | Frome Bruce Marshall | Topical and oral administration of a composition containing Pelargonium Graveolens for diagnosis and treatment of various neuralgias and other conditions |
CA2522028C (en) * | 2003-04-10 | 2011-11-01 | Neurogesx, Inc. | Methods and compositions for administration of trpv1 agonists |
US20050025823A1 (en) * | 2003-07-29 | 2005-02-03 | Fong Andy A.T. | Methods of use of herbal compositions |
US20050112183A1 (en) | 2003-11-25 | 2005-05-26 | Galer Bradley S. | Compositions and methods for treating neuropathic sensory loss |
US20060004050A1 (en) | 2004-07-02 | 2006-01-05 | Speicher Brian T | Compositions and methods for the prevention or treatment of pain and other nervous system disorders |
US20060222690A1 (en) * | 2005-03-30 | 2006-10-05 | Bley Keith R | Low-concentration capsaicin patch and methods for treating neuropathic pain |
US20070203080A1 (en) | 2006-02-15 | 2007-08-30 | The Regents Of The University Of California | New Drug Delivery System for Crossing the Blood Brain Barrier |
WO2008108825A2 (en) | 2006-10-10 | 2008-09-12 | Burnham Institute For Medical Research | Neuroprotective compositions and methods |
EP2446903B1 (en) * | 2006-11-20 | 2019-10-09 | President and Fellows of Harvard College | Compositions for treating itch |
JP5933164B2 (ja) | 2007-02-06 | 2016-06-08 | ニューロクエスト インク | テルペン化合物を含む組成物及び神経伝達の抑制方法 |
WO2009064845A2 (en) | 2007-11-16 | 2009-05-22 | Bernstein Eric F | Sterilizing compositions comprising phosphors for converting electromagnetic radiation to uvc radiation and methods for using the same |
GB2460214A (en) | 2008-03-20 | 2009-11-25 | Hexcel Composites Ltd | Prepregs for use in making laminates of reduced porosity |
FR2934925B1 (fr) * | 2008-08-06 | 2011-02-25 | Soitec Silicon On Insulator | Procede de fabrication d'une structure comprernant une etape d'implantations d'ions pour stabiliser l'interface de collage. |
EP2326323A4 (en) | 2008-08-13 | 2012-02-22 | Neuroquest Inc | COMPOSITION COMPRISING TERPENE COMPOUNDS FOR THE TREATMENT OF NEGATIVE SENSORY PHENOMENA |
WO2010057295A1 (en) | 2008-11-18 | 2010-05-27 | Origin Biomed Inc. | Homeopathic composition comprising hypericum perforatum extract and essential oils for the treatment of neuropathic pain |
JP2013538218A (ja) | 2010-09-14 | 2013-10-10 | ニューロクエスト インク | 神経疾患を治療するためのテルペノイド類似体およびその使用 |
CA2841972A1 (en) | 2011-07-14 | 2013-01-17 | Neuroquest Inc. | Terpene analogues and uses thereof for treating neurological conditions |
-
2008
- 2008-02-06 JP JP2009548553A patent/JP5933164B2/ja not_active Expired - Fee Related
- 2008-02-06 KR KR20157008120A patent/KR20150046328A/ko not_active Application Discontinuation
- 2008-02-06 AU AU2008213772A patent/AU2008213772A1/en not_active Abandoned
- 2008-02-06 CA CA2676139A patent/CA2676139C/en active Active
- 2008-02-06 WO PCT/CA2008/000236 patent/WO2008095297A1/en active Application Filing
- 2008-02-06 KR KR1020097018619A patent/KR101580857B1/ko not_active IP Right Cessation
- 2008-02-06 EP EP08714559.5A patent/EP2142182B1/en not_active Not-in-force
- 2008-02-06 CN CN201511021134.2A patent/CN105581999A/zh active Pending
- 2008-02-06 CN CN200880006917A patent/CN101677973A/zh active Pending
-
2009
- 2009-08-06 US US12/537,095 patent/US9999601B2/en active Active
-
2016
- 2016-01-27 JP JP2016013591A patent/JP6144785B2/ja not_active Expired - Fee Related
- 2016-11-04 HK HK16112719.7A patent/HK1224231A1/zh unknown
-
2018
- 2018-01-19 US US15/875,060 patent/US20180207110A1/en not_active Abandoned
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103153297A (zh) * | 2010-09-14 | 2013-06-12 | 安元有限公司 | 类萜类似物及其用于治疗神经病症的用途 |
CN104284668A (zh) * | 2012-05-07 | 2015-01-14 | 以色列国家农业和农村发展部农业科研组织(Aro)(沃尔卡尼中心) | 用于治疗神经变性疾病的天竺葵精油及其成分 |
CN104284668B (zh) * | 2012-05-07 | 2018-04-20 | 以色列国家农业和农村发展部农业科研组织(Aro)(沃尔卡尼中心) | 用于治疗神经变性疾病的天竺葵精油及其成分 |
US11793767B2 (en) | 2012-05-07 | 2023-10-24 | The State Of Israel, Ministry Of Agriculture & Rural Development Agriculture Research Organization | Geranium oil and constituents thereof for treatment of neurodegenerative diseases |
CN104918614A (zh) * | 2012-09-28 | 2015-09-16 | 株式会社资生堂 | Vegfc产生促进剂 |
CN104918614B (zh) * | 2012-09-28 | 2018-10-16 | 株式会社资生堂 | Vegfc产生促进剂 |
US10624829B2 (en) | 2012-09-28 | 2020-04-21 | Shiseido Company, Ltd. | VEGFC production promoter |
US11213472B2 (en) | 2012-09-28 | 2022-01-04 | Shiseido Company, Ltd. | VEGFC production promoter |
CN105637363A (zh) * | 2013-08-01 | 2016-06-01 | 庆熙大学校产学协力团 | 预防或治疗糖尿病的药物组合物,预防或治疗糖尿病的方法,以及筛选糖尿病治疗药物的方法 |
US10493042B2 (en) | 2013-08-01 | 2019-12-03 | University-Industry Cooperation Group Of Kyung Hee University | Method for preventing or treating diabetes mellitus, and method for screening for diabetes mellitus therapeutic agent |
US11311497B2 (en) | 2013-08-01 | 2022-04-26 | University—Industry Corporation Group of Kyung Hee University | Method for screening for diabetes mellitus therapeutic agents |
Also Published As
Publication number | Publication date |
---|---|
US20110257255A1 (en) | 2011-10-20 |
JP2016121169A (ja) | 2016-07-07 |
WO2008095297A1 (en) | 2008-08-14 |
EP2142182A4 (en) | 2010-03-03 |
KR20150046328A (ko) | 2015-04-29 |
KR101580857B1 (ko) | 2015-12-30 |
EP2142182A1 (en) | 2010-01-13 |
KR20100014922A (ko) | 2010-02-11 |
HK1224231A1 (zh) | 2017-08-18 |
EP2142182B1 (en) | 2017-09-27 |
US9999601B2 (en) | 2018-06-19 |
AU2008213772A1 (en) | 2008-08-14 |
CA2676139A1 (en) | 2008-08-14 |
JP2010518030A (ja) | 2010-05-27 |
CN105581999A (zh) | 2016-05-18 |
CA2676139C (en) | 2016-04-26 |
JP6144785B2 (ja) | 2017-06-07 |
JP5933164B2 (ja) | 2016-06-08 |
US20180207110A1 (en) | 2018-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101677973A (zh) | 用于抑制神经传导的包括萜烯化合物的组合物以及方法 | |
DE69715899T2 (de) | Zusammensetzungen zur behandlung der peripheren neuropathie, die antidepressiven verbindungen und/oder monoamino-oxidaseinhibitoren und/oder vitamin b12 und/oder neurotransmitter-vorläufer oder induktoren enthalten | |
US20160317466A1 (en) | Compositions comprising terpene compounds for treating negative sensory phenomena | |
CA2743967A1 (en) | Homeopathic composition comprising hypericum perforatum extract and essential oils for the treatment of neuropathic pain | |
US20030224072A1 (en) | Topical and oral administration of a composition containing Pelargonium Graveolens for diagnosis and treatment of various neuralgias and other conditions | |
Kozuharova et al. | Chemical composition and comparative analysis of lavender essential oil samples from Bulgaria in relation to the pharmacological effects | |
Imam et al. | The Cream which relieves the pain of Menstrual cramps without interfering with the Hormones or Period Cycle | |
DE69529819T2 (de) | Neue kombination eines betablockers mit einem lokalanästhetikum | |
WO2020115751A1 (en) | Cannabis-based compositions for the treatment of alzheimer's disease and dementia | |
US20170136081A1 (en) | Composition and method for the treatment of neuropathic pain | |
Dong et al. | Pharmacological effect of Panax notoginseng saponins on cerebral ischemia in animal models | |
CN100370973C (zh) | 一种治疗胸痹的中药制剂 | |
CN103908567A (zh) | 一种用于治疗糖尿病痛性神经病变的复方制剂及其应用 | |
Kalam | Evaluation of Anticonvulsant Activity of Aqer Qerha (Anacyclus pyrethrum DC) root in Experimental Animals | |
EP0358683A1 (de) | Pharmazeutikum | |
McLellan et al. | Compositions comprising terpene compounds for treating negative sensory phenomena | |
JP2880537B2 (ja) | 催眠促進剤 | |
WO2021151185A1 (pt) | Fitoterápico, fitofármaco e uso de ambos | |
Mannucci | TS Elvira Ventura Spagnolo | |
Grasse | Traditional Uses of Essential Oils in Light of Receptor Science | |
WO2005000326A1 (de) | Peptidtoxine zur behandlung von übergewicht |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: SAFIRST CO., LTD. Free format text: FORMER OWNER: ORIGIN BIOMEDICINALS INC. Effective date: 20120214 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20120214 Address after: Nova Scotia Canada Applicant after: Neuroquest Inc. Co-applicant after: Luis Anna State University Monitoring Committee, College of agriculture and Mechanical Engineering Address before: Nova Scotia Canada Applicant before: Origin Biomed Inc Co-applicant before: Luis Anna State University Monitoring Committee, College of agriculture and Mechanical Engineering |
|
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20100324 |